QAM
GALT icon

QCI Asset Management’s Galectin Therapeutics GALT Stock Holding History

QCI Asset Management’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$213K Buy
55,000
+30,000
+120% +$102K 0.01% 147
2021
Q2 		$80K Buy
+25,000
New +$89K ﹤0.01% 156

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

QCI Asset Management's GALT Position: Q3 2021 in Review

QCI Asset Management increased its Galectin Therapeutics (GALT) stake by 120% in Q3 2021, buying an estimated $102K and bringing the position to 55,000 shares worth $213K. The position accounts for 0.01% of the portfolio, ranked #147.

QCI Asset Management first reported a position in GALT in Q2 2021 and has held it in 2 quarters since. 70 funds tracked by Wall St. Rank hold GALT as of Q3 2021.

  • QCI Asset Management held 55,000 shares of Galectin Therapeutics worth $213K as of Q3 2021.
  • QCI Asset Management bought 30,000 Galectin Therapeutics shares in Q3 2021, an estimated $102K.
  • Galectin Therapeutics made up 0.01% of QCI Asset Management's portfolio in Q3 2021, its #147 holding.
  • QCI Asset Management first reported a position in Galectin Therapeutics in Q2 2021 and has held it in 2 quarters since.
  • 70 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2021.

Based on QCI Asset Management's 13F filing for Q3 2021, filed 4 Nov 2021.